Deal Statistics Quarterly, Q3 2000
Executive Summary
In Vivo presents the second installment of a new quarterly feature--a statistical review compiled from Windhover's Strategic Transactions Database of the deal activity within the pharmaceuticals, biotechnology, medical device and in vitro diagnostics industries.
You may also be interested in...
Coronavirus Update: After 'Warp Speed' Snub, Novavax Awarded US Military Vaccine Deal
Progress for two US-based companies in the race to develop a COVID-19 vaccine.
QUOTED. 5 June 2020. US FDA.
A new document from the US FDA details acceptable substitutions for COVID-19 testing components that may be difficult to come by. See what the regulatory agency said about it here.
CIR Expert Panel Rebranded Ahead Of June Virtual Meeting
The renamed Expert Panel for Cosmetic Ingredient Safety has its own website now, which includes the conflict of interest statement its members are expected to sign. The panel will meet virtually 8-9 June to consider a raft of ingredient reports in various stages of development at Cosmetic Ingredient Review.
Need a specific report? 1000+ reports available
Buy Reports